PACB vs TXG
PACB: PacBio provides high-accuracy, long-read DNA sequencing platforms designed to solve complex genomic challenges for research and clinical applications. TXG: 10x Genomics provides advanced single-cell and spatial biology platforms that empower researchers to decode complex biological systems at high resolution.
Side-by-side fundamentals
| Metric | PACB | TXG | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.30 | $77.28 | |
| Market cap | $715M | $9.9B | |
| Net margin FY2025, SEC XBRL | n/a | -6.8% | |
| Gross margin FY2025, SEC XBRL | n/a | +69.1% | |
| Operating margin FY2025, SEC XBRL | n/a | -9.5% | |
| ROE FY2025, SEC XBRL | -10214.5% | -5.5% | TXG higher |
| ROA FY2025, SEC XBRL | -69.7% | -4.2% | TXG higher |
| Debt / equity as of 2026-09-02 | 272.23 | 0.00 | TXG lower |
| Revenue growth (YoY) as of 2026-09-02 | +2.0% | -4.3% | PACB higher |
| Revenue CAGR (3y) SEC XBRL | -6.9% | +7.6% | TXG higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.89 | 1.92 | |
| 1-year return as of 2026-10-08 close | +52.3% | +540.3% | TXG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.